This medication requires a valid prescription. Please refer to the ‘Prescription Guide’ for details.
Note: We can assist only if the medicine is unavailable in your country.”
Shipping:
Cold Chain Shipping.
Datroway (datopotamab deruxtecan-dlnk) is shipped under temperature-controlled conditions (2°C to 8°C) to preserve its stability and effectiveness. Specialized medical couriers use insulated packaging and monitored delivery to maintain proper storage throughout transit.
Disease Indications:
- Breast Cancer (Unresectable or Metastatic HR-positive, HER2-negative)
Manufacturer:
Daiichi Sankyo Co., Ltd. / AstraZeneca
Usage:
Intravenous (IV) infusion
Datroway (datopotamab deruxtecan-dlnk)
General Description:
Datroway (datopotamab deruxtecan-dlnk) is an advanced antibody-drug conjugate (ADC) therapy developed for adults with unresectable or metastatic HR-positive, HER2-negative breast cancer. It targets the Trop-2 protein, which is commonly overexpressed in many cancer cells, delivering a potent chemotherapy agent directly into the tumor. This targeted mechanism helps destroy cancer cells while minimizing damage to healthy tissues.
Datroway is administered intravenously and is available in lyophilized powder form (100 mg per single-dose vial). The medicine must be prepared and infused by a qualified healthcare professional.
Getting Datroway (datopotamab deruxtecan-dlnk) in India
While Datroway (datopotamab deruxtecan-dlnk) has received approval from the U.S. Food and Drug Administration (FDA) and Japan’s Pharmaceuticals and Medical Devices Agency (PMDA), it is not yet commercially available in India. However, eligible patients can access the medication through the Named Patient Program (NPP) in accordance with Indian regulatory provisions.
MitoGENE assists Indian patients in obtaining Datroway (datopotamab deruxtecan-dlnk) safely and legally under medical supervision. Our team manages the necessary paperwork, import permissions, and cold-chain logistics to ensure the medicine reaches you in perfect condition and full compliance with local laws.
If you or someone you care for may benefit from Datroway (datopotamab deruxtecan-dlnk), MitoGENE is here to guide you through every step of the access process.
Medicine Approved by:
- Food and Drug Administration (FDA)
- Pharmaceuticals and Medical Devices Agency (PMDA)
- European Medicines Agency (EMA) – approval anticipated following CHMP positive recommendation
Available Dosage Form & Package:
- 100 mg lyophilized powder in a single-dose vial
How to Access Datroway (datopotamab deruxtecan-dlnk) in India in 4 Simple Steps with MitoGENE via the Named Patient Program (NPP)?
If Datroway (datopotamab deruxtecan-dlnk) is not yet approved or commercially available in India, MitoGENE can assist you in accessing it legally through the Named Patient Program (NPP). Here’s how the process works:
